HIGHLIGHTS
SUMMARY
As the current largest group purchasing organization in the world, certainly, the NCDP initiative in China has generally successfully established a "buyer-cartels" to countervail pharmaceutical companies for quality drugs at lower prices (Huff-Rousselle, 2012; Xing et_al, 2022). Despite years of radical commitment to a drug price reduction in China, the lack of strong purchasing/negotiation power, integrated pricing strategy, standardized pricing principles, as well as efficient financial incentives have still hindered the establishment of a rational drug-pricing mechanism for the last 2 decades (Hu and Mossialos, 2016; Jiang et_al, 2021), which . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.